Literature DB >> 3481335

Pharmacokinetics and tissue penetration of orally administered pefloxacin.

J M Webberley1, J M Andrews, J P Ashby, A McLeod, R Wise.   

Abstract

The pharmacokinetics of the quinolone pefloxacin were determined following a 400 mg oral dose given to each of six male volunteers. Concentrations were determined in serum and urine by high-performance liquid chromatography, and in cantharidin-induced inflammatory fluid by a microbiological assay. The mean peak serum level of 6.6 micrograms/ml was attained rapidly 0.8 h after administration. The mean serum elimination half-life was 11.6 h. Inflammatory fluid was penetrated quickly with a mean peak level of 3.9 micrograms/ml occurring at 2.4 h. Pefloxacin was excreted in the urine as the parent compound and its two metabolites, norfloxacin and pefloxacin N-oxide (24 h urinary recovery being 8.0%, 12.0% and 13.1% respectively of the dose). This study suggests that a twice or possibly once daily dosage may be sufficient to treat systemic infections caused by susceptible pathogens. Once daily dosing should be sufficient for urinary tract infections.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3481335     DOI: 10.1007/BF02014239

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  17 in total

1.  The comparative pharmacokinetics of five quinolones.

Authors:  R Wise; D Lister; C A McNulty; D Griggs; J M Andrews
Journal:  J Antimicrob Chemother       Date:  1986-11       Impact factor: 5.790

2.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

3.  Efficacy and safety of pefloxacin in the treatment of patients with complicated urinary tract infections.

Authors:  J B Boerema; R Pauwels; J Scheepers; W Crombach
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

4.  The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics.

Authors:  R Wise; A P Gillett; B Cadge; S R Durham; S Baker
Journal:  J Infect Dis       Date:  1980-07       Impact factor: 5.226

5.  Pefloxacin kinetics in cirrhosis.

Authors:  G Danan; G Montay; R Cunci; S Erlinger
Journal:  Clin Pharmacol Ther       Date:  1985-10       Impact factor: 6.875

6.  Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers.

Authors:  A M Frydman; Y Le Roux; M A Lefebvre; F Djebbar; J B Fourtillan; J Gaillot
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

7.  Transfer kinetics of pefloxacin into cerebro-spinal fluid after one hour i.v. infusion of 400 mg in man.

Authors:  J Dow; J Chazal; A M Frydman; P Janny; R Woehrle; F Djebbar; J Gaillot
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

8.  Efficacy of pefloxacin in comparison with erythromycin in the treatment of experimental guinea pig legionellosis.

Authors:  E Dournon; P Rajagopalan; J L Vilde; J J Pocidalo
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

9.  Efficacy and safety of pefloxacin in the treatment of severe infections in patients hospitalized in intensive care units.

Authors:  S Lauwers; W Vincken; A Naessens; D Pierard
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

10.  In-vitro activity of newer quinolones against aerobic bacteria.

Authors:  R Auckenthaler; M Michéa-Hamzehpour; J C Pechère
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

View more
  7 in total

1.  Pharmacokinetics and tissue penetration of orally administered lomefloxacin.

Authors:  J W Stone; J M Andrews; J P Ashby; D Griggs; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

2.  Penetration of pefloxacin and its desmethyl metabolite into the uroepithelium after a 800-mg single oral dose in human patients.

Authors:  J L Moreau; M J Royer-Morrot; A Lozniewski; G Trackoen; P Delavault; R J Royer
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

Review 3.  Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Gonzalez; J M Henwood
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

Review 4.  Quinolones in urology.

Authors:  K T Nielsen; P O Madsen
Journal:  Urol Res       Date:  1989

Review 5.  Pharmacokinetics of quinolones: newer aspects.

Authors:  J S Wolfson; D C Hooper
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

Review 6.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

Review 7.  Pefloxacin clinical pharmacokinetics.

Authors:  F Bressolle; F Gonçalves; A Gouby; M Galtier
Journal:  Clin Pharmacokinet       Date:  1994-12       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.